Inclusion on list of products reimbursed by National Insurance and for hospital use.
-
Clinical Benefit
Substantial
The actual benefit of FIRMAGON is substantial.
Clinical Added Value
no clinical added value
In the context of the current strategy for treatment of advanced prostate cancer, with a combination of a Gn-RH analogue and an antiandrogen in the first month of treatment, FIRMAGON provides no improvement in actual benefit (IAB level V).
Listen
